|
Market Closed -
NYSE
16:00:00 2026-09-29 EDT
|
5-day change | 1st Jan Change | ||
| 1.140 USD | -3.39% |
|
-2.56% | -16.18% |
| 08-14 | Actinium Pharmaceuticals Expands Manufacturing Capacity for Actimab-A Program | CI |
| 08-14 | Actinium Pharmaceuticals, Inc. Amends Its Investigational New Drug | CI |
Company Valuation: Actinium Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 132.4 | 271.4 | 139.3 | 39.31 | 42.43 | 35.84 | - | - |
| Change | - | 104.97% | -48.69% | -71.77% | 7.94% | -15.52% | - | - |
| Enterprise Value (EV) | 132.4 | 271.4 | 62.58 | 39.31 | 42.43 | 35.84 | 35.84 | 35.84 |
| Change | - | 104.97% | -76.94% | -37.19% | 7.94% | -15.52% | 0% | 0% |
| P/E | -5.01x | -7.77x | -2.78x | -0.99x | -1.25x | 6.45x | -1.7x | -2.94x |
| PBR | 1.81x | - | 3.72x | - | - | - | - | - |
| PEG | - | -0.5x | -0.1x | 0x | 0.1x | -0x | 0x | 0.1x |
| Capitalization / Revenue | 116x | 263x | 1,719x | - | 471x | 2.05x | - | 2.05x |
| EV / Revenue | 0x | 0x | 0x | - | 0x | 2.05x | - | 2.05x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | 14.9x | -0.97x | -0.87x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | 6.89x | -1.07x | -1.6x |
| EV / FCF | -0x | 0x | -0x | -0x | - | 1.66x | -1.33x | -1.48x |
| FCF Yield | -15.9% | 3.05% | -34.1% | -84.2% | - | 60.3% | -75.4% | -67.8% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.2 | -1.37 | -1.83 | -1.27 | -1.09 | 0.1767 | -0.67 | -0.3875 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1.144 | 1.03 | 0.081 | - | 0.09 | 17.5 | - | 17.46 |
| EBITDA 1 | -24.44 | -33.4 | -51.13 | -41.31 | -35.43 | 2.4 | -37.1 | -41.1 |
| EBIT 1 | -24.96 | -34.1 | -51.92 | -42.12 | -36.25 | 5.201 | -33.35 | -22.45 |
| Net income 1 | -24.77 | -33.02 | -48.82 | -38.24 | -33.89 | 5.912 | -30.95 | -19.95 |
| Net Debt | - | - | -76.68 | - | - | - | - | - |
| Reference price 2 | 6.010 | 10.650 | 5.080 | 1.260 | 1.360 | 1.140 | 1.140 | 1.140 |
| Nbr of stocks (in thousands) | 22,031 | 25,483 | 27,413 | 31,196 | 31,196 | 31,441 | - | - |
| Announcement Date | 3/25/22 | 3/31/23 | 3/29/24 | 3/31/25 | 3/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 6.68x | - | - | - | 37.1M | |
| 21.02x | 7.45x | 14.97x | 1.41% | 71.81B | |
| 31.2x | 8.99x | 28.02x | 0.04% | 60.06B | |
| 32.35x | 6.9x | 17.92x | -.--% | 27.93B | |
| -72.02x | 13.86x | -70.68x | -.--% | 25.7B | |
| -15.29x | 5.82x | -7.32x | -.--% | 24.89B | |
| 28.77x | 5.41x | 17.98x | -.--% | 20.92B | |
| 42.74x | 15.97x | 32.4x | 0.35% | 15.04B | |
| 18.03x | 5.37x | 12.55x | -.--% | 14.46B | |
| 990.12x | 34.59x | 597.44x | -.--% | 13.87B | |
| Average | 108.36x | 11.60x | 71.48x | 0.2% | 27.47B | |
| Weighted average by Cap. | 62.95x | 9.76x | 38.56x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATNM Stock
- Valuation Actinium Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
